Loading HIMS detail
Loading ticker data...
Loading HIMS detail
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals.
The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Chart data unavailable
Hims & Hers announced its strategy around AI and how it fits into the company's platform. AI could enable more products and solutions for users outside of traditional prescriptions.
Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) CFO Oluyemi Okupe sold 3,975 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $19.98, for a total value of $79,420.50. Following the sale, the chief financial officer directly owned 318,789 shares
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at about $20 on Wednesday, down almost 39% so far this year.
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Hims & Hers Health is evolving from a telehealth provider into a scalable, global consumer health platform with diversified growth drivers. The Novo Nordisk partnership validates HIMS' platform, but execution and regulatory risks in obesity treatments remain material to the thesis. International expansion, notably the Eucalyptus acquisition, and new service categories support robust revenue growth and platform monetization.
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings...
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08% move from the preceding trading day.
American Express, KKR, and other financial stocks are trading at multi-year low valuations, and insider buying at KKR suggests the private credit panic may be overdone.
HIMS is broadening its digital-first platform with Labs, hormone therapy and weight-loss programs as it scales personalized care globally.
Shares of Hims and Hers Health, Inc. (NYSE: HIMS - Get Free Report) have been given an average recommendation of "Hold" by the seventeen ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have issued a buy
SAN FRANCISCO, April 03, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is actively investigating data privacy claims arising from the Hims & Hers, Inc. data breach. On February 5, 2026, Hims & Hers, Inc. discovered a data breach affecting its computer network.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS). On June 23, 2025, Novo Nordisk announced that it was terminating its partnership with Hims & Hers, disclosing that the Company had “failed to adhere to the law which prohibits mass sales of compounde.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers (HIMS 3.53%) has been one of the most volatile stocks in the markets in recent months.
